{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=28", "query": { "intervention": "serum sample", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 8371, "total_pages": 838, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T13:23:27.110Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01574157", "title": "Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Renal Insufficiency", "Diabetes Mellitus" ], "interventions": [ { "name": "Sodium bicarbonate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2012-11-05", "completion_date": "2018-05-01", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01574157" }, { "nct_id": "NCT00462865", "title": "Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gemcitabine and Capecitabine and Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2019-04-09", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 3, "location_summary": "Albuquerque, New Mexico • Providence, Rhode Island", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462865" }, { "nct_id": "NCT00756964", "title": "Lowering Serum Uric Acid to Prevent Acute Kidney Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperuricemia" ], "interventions": [ { "name": "Rasburicase", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2008-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2012-09-03", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00756964" }, { "nct_id": "NCT07446322", "title": "FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ras-mutated Metastatic Colorectal Cancer", "mCRC", "MSS Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Pelareorep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-04-30", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 17, "location_summary": "Homewood, Alabama • Beverly Hills, California • Encino, California + 13 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Koreatown", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07446322" }, { "nct_id": "NCT02198651", "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis", "Musculoskeletal and Connective Tissue Diseases" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2015-01-05", "completion_date": "2018-08-08", "has_results": true, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 13, "location_summary": "Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Monroe", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02198651" }, { "nct_id": "NCT00550992", "title": "Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "prednisolone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Dutch Childhood Oncology Group", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "ALL", "summary": "Up to 1 Year" }, "enrollment_count": 445, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Memphis, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550992" }, { "nct_id": "NCT03680092", "title": "Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GVHD", "Hematologic Neoplasms" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "abatacept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dimitrios Tzachanis, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-11-26", "completion_date": "2023-06-15", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03680092" }, { "nct_id": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "NSCLC", "Hepatocellular Carcinoma", "Urothelial Cancer", "Gastric Adenocarcinoma", "HNSCC", "Esophageal Adenocarcinoma", "Microsatellite Instability-High Solid Malignant Tumor" ], "interventions": [ { "name": "Nivolumab or Pembrolizumab (dependent upon approved indication)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Rosiglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2020-09-14", "completion_date": "2032-04-30", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04114136" }, { "nct_id": "NCT01665599", "title": "A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adult Male Hypogonadism" ], "interventions": [ { "name": "Testosterone gel (FE 999303)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 180, "start_date": "2012-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 17, "location_summary": "Huntsville, Alabama • Newport Beach, California • San Diego, California + 14 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Middlebury", "state": "Connecticut" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01665599" }, { "nct_id": "NCT01811498", "title": "Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Brain Tumor" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2013-02", "completion_date": "2021-10", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-18T13:23:27.110Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01811498" } ] }